Company: MBIO
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001104659-25-108468
Chunk: 3

Company: MUSTANG BIO, INC.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part II, Item 1L
Chunk 3
---
 amount of increased expenses or when or if, we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if:

●one or more of our product candidates receive regulatory approval and are approved for commercial sale, due to our need to establish the necessary commercial infrastructure to launch and commercialize this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities;

●we are required by the FDA or foreign regulatory authorities to perform studies in addition to those currently expected;

●there are any delays in completing our clinical trials or the development of any of our product candidates;

●we execute other collaborative, licensing or similar arrangements that require us to make payments to collaborators or licensors;

●there are variations in the level of expenses related to our future development programs;

●there are any product liability or intellectual property infringement lawsuits in which we may become involved; and

●there are any regulatory developments affecting product candidates of our competitors.